CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 493 enrolled
Drug / intervention
Epaxal Berna (virosomal hepatitis A vaccine)biological
Likely dose
Epaxal Berna (virosomal hepatitis A vaccine) 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01341808
NCT01341808Phase 4Completed
CompareCT.gov

Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease

Asan Medical Center·interventional·Posted Apr 26, 2011·Updated Mar 19, 2013

In Brief

A Phase 4 clinical trial evaluating Epaxal Berna (virosomal hepatitis A vaccine) for Inflammatory Bowel Disease and 3 related conditions. Completed, enrolled 493 participants across 1 site.

Detailed Summary

The purpose of this study is to measure the immune response in 18-40 year old IBD patients after receiving the hepatitis A vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Hepatitis A
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 26, 2011
Enrollment StartApr 1, 2011
Primary CompletionFeb 1, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.2 years ago

Interventions

Epaxal Berna (virosomal hepatitis A vaccine)biological

standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.